Vaccines approved for invasive pneumococcal disease and meningococcal disease

Article

Pfizer's pneumococcal 13-variant conjugate vaccine (Prevnar 13) was approved by the FDA for active immunization of children aged 6 weeks through 5 years for the prevention of invasive disease caused by 13 Streptococcus pneumoniae serotypes.

Pfizer's pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) (Prevnar 13) was approved by the FDA for active immunization of children aged 6 weeks through 5 years for the prevention of invasive disease caused by 13 Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. The vaccine was also approved for the prevention of otitis media caused by serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.

Novartis received approval from the FDA for a meningococcal (groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (Menveo) for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitides serogroups A, C, Y, and W-135 in patients aged 11 to 55 years.

Recent Videos
Joshua Feder, MD
Zika-based therapy for metastatic neuroblastoma with Tamarah Westmoreland, MD and Joseph Mazar, PhD | Image Credit: © Nemours- © Nemours - stock.adobe.com.
Geetika Kennady, MD, FAAP
Jillian Cotter, MD
Jesse Hinckley, MD, PhD
Validating digital stethoscope for pediatric breath sounds, with Jennifer Nestor, MD
Decreasing antibiotics for acute otitis media and community acquired pneumonia, with Elysha Pifko, MD
Sensory play for children with autism, with Joshua Feder, MD
© 2025 MJH Life Sciences

All rights reserved.